Improving drug delivery to brain tumors using new compounds
Official title: ENHANCEMENT OF BBB CROSSING OF AR DEGRADERS IN GBM
Funded at Cleveland State University · NIH-11040457 · Data updated 2026-11-12
This study is looking at a new treatment for glioblastoma, a tough brain tumor, by testing small molecules that can help break down a protein that often makes the tumor worse, especially in men, to see if they work better than the usual chemotherapy.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland State University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | April 1, 2021 |
| Project end | March 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $445,500 |
| NIH project number | 2R15NS116766-02 |
| Project ID | NIH-11040457 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adult patients diagnosed with glioblastoma, particularly those who have shown resistance to standard treatments.
✕Less likely to help
Patients with glioblastoma who are not eligible for experimental therapies or those with other significant health issues may not benefit from this research.
What this research studies
This research focuses on glioblastoma (GBM), a highly aggressive brain tumor with a poor prognosis. The team is investigating a new class of small molecules designed to degrade the androgen receptor, which is overexpressed in many GBM cases, particularly in male patients. By enhancing the ability of these compounds to cross the blood-brain barrier, they aim to improve treatment outcomes compared to the current standard chemotherapy, Temozolomide. The research includes testing these compounds in patient-derived models to assess their effectiveness and safety.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have gone: While the approach of using androgen receptor degraders is relatively novel, similar strategies targeting the blood-brain barrier have shown promise in other cancer treatments.
Where this research is happening
-
Cleveland State University
Cleveland, United States Active
Researchers
- Principal investigator: Su, Bin — Cleveland State University
- Study coordinator: Su, Bin
Related research
Other NIH-funded projects on the same topics.
-
How ATP8B1 and ABCA1 affect cholesterol and inflammation in heart disease
A research project is exploring how specific cholesterol-related proteins influence inflammation and heart disease to uncover new ways to prevent or treat atherosclerosis.
-
Circadian Clock and Diet: How calories and timing affect aging
A study exploring how calorie restriction and daily rhythms interact to influence aging-related metabolism and signaling in mice, with potential relevance to human aging.
-
Wireless pudendal nerve stimulation to reduce urine leakage after childbirth
A tiny wireless device that uses mechanical motion to make gentle electrical pulses to the nerve that controls the urethral muscle, aimed at helping women with stress urinary incontinence after vaginal delivery.
-
New LC-MS/MS instrument to boost research and education at CSU
CSU is requesting a high-end LC-MS/MS instrument to upgrade its research labs and provide hands-on training for students and faculty.
-
Multi-functional 3D-Printed Dental Implants to Prevent Peri-Implant Infections
A patient-friendly implant made with a special 3D-printed material that fights infection and helps bone integrate with the implant.
-
Lowering PUM1 to raise fetal hemoglobin in adults
Seeing if reducing a protein called PUM1 can raise protective fetal hemoglobin in adults with sickle cell disease or beta‑thalassemia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.